Criteria Bio Ventures is a venture capital firm established in 2007 and headquartered in Barcelona, Spain. The firm specializes in investing in private biotechnology and life sciences companies, primarily targeting opportunities in Europe and North America, with a particular emphasis on the markets of Spain and Portugal. Through its investments, Criteria Bio Ventures aims to support the growth and development of innovative companies within the biotech sector.
Tolerance Bio is a biopharmaceutical company dedicated to extending healthspan by restoring and preserving the function of the thymus, a critical organ for immune system regulation. The company's innovative approach involves creating artificial, bio-engineered thymus tissue using induced pluripotent stem cells (iPSCs), which can then be used to establish and maintain immune tolerance in patients, potentially treating a wide range of immune-mediated diseases.
MedLumics
Venture Round in 2024
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.
AbolerIS Pharma
Series A in 2023
AbolerIS Pharma is a biotechnology company based in Nantes, France, focused on developing immune-modulators for the treatment of transplant rejection, graft-versus-host disease, and autoimmune diseases. Established in 2019, the company employs a unique therapeutic approach that aims to induce immune tolerance while preserving beneficial immune responses in various inflammatory and degenerative conditions. Its product portfolio includes Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma's innovative strategies enable researchers to advance novel drug development in areas with significant unmet medical needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.